Prolonged Progression Free Survival In A Subset Of Responders To The Combination Of Brentuximab Vedotin And Bendamustine In Heavily Treated Patients With Relapsed Or Refractory Hodgkin Lymphoma: Updated Results From An International Multi-Center Phase I/Ii Experience

Ahmed Sawas,Helen Ma,John Kuruvilla,Jennifer K Lue,Changchun Deng,Enrica Marchi,Francesca Montanari,Bin Cheng,Kerry J Savage,Diego Villa,Michael Crump,Joseph M Connors,Owen A O'Connor

LEUKEMIA & LYMPHOMA（2020）

引用 2|浏览5

暂无评分

摘要

Classical Hodgkin lymphoma (cHL) is a malignancy that arises from clonal germinal center B-cells [1]. Despite favorable outcomes in the front-line setting for most patients, 20–30% of patients deve...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要